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Abstract
The aims of this study were to compare the characteristics of adult patients with left-sided infective endocarditis (LSIE) diagnosed and
treated in a tertiary-care hospital with those of patients referred from a second-level community hospital, and to establish the accuracy
of diagnosis and adequacy of treatment in referred patients and the influence of this factor on outcome. A prospective observational
cohort study was conducted at Hospital Universitari Vall d’Hebron, a 1000-bed teaching hospital in Barcelona (Spain) and a referral cen-
tre for cardiac surgery. One hundred and fourteen of 337 (34%) episodes of LSIE treated in our hospital occurred in transferred
patients. As compared with patients diagnosed in our hospital, transferred patients acquired LSIE within the healthcare system less often
(16.7% vs. 38.1%, p <0.001), were in better health (Charlson index 3 (interquartile range (IQR)) 1–4) vs. 4 (IQR 2–6), p <0.001), had
more complications (94.7% vs. 78.9%, p <0.001), underwent more operations (69.3% vs. 22.1%, p <0.001), and experienced similar mor-
tality (22.8% vs. 31.4%, p 0.100). Only 52 of 114 (45.6%) referred patients received an antimicrobial regimen included in the American,
European or Spanish guidelines at the hospital of origin. After adjustment for congestive heart failure and staphylococcal infection in
multivariate logistic regression, inadequate or no antimicrobial treatment at origin was a risk factor for in-hospital mortality (OR 3.3,
95% CI 1.1–10.0, p 0.030). Errors in the initial antimicrobial treatment prescribed for LSIE are associated with greater mortality.
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Introduction
In developed countries, population-based studies show that
the incidence of infective endocarditis (IE) ranges between
2.6 and 5.4 cases per 100 000 population per year [1]. Thus,
it is estimated that family doctors will diagnose a single case
of IE over the duration of their professional career.
Despite improvements in the diagnosis and surgical treat-
ment of IE, this disease continues to be associated with high
rates of morbidity and mortality [2–5]. Although there are
consensus statements on the diagnosis, treatment and
management of patients with IE, both international and
national [6–8], daily clinical practice often diverges from the
recommendations. These two facts are justified by the
changing profile of IE in developed countries in recent years
[9]. Currently, IE is mainly caused by staphylococci, and
affects an increasing number of frail patients in close contact
with the health system [5,10,11]. In this context, multidisci-
plinary teams of experienced cardiologists, infectious disease
specialists, microbiologists and cardiac surgeons are needed
to optimize the management of IE patients.
To date, few studies have focused on the selection bias in
IE patients transferred to hospitals with cardiac surgery
departments [12], or the reasons for the transfer [2]. In
addition, there is only one published study evaluating the
quality of IE management, although it did not analyse the
influence of this factor on outcome [13].
The aims of this study were: (i) to compare the character-
istics of adult patients with left-sided IE (LSIE) diagnosed and
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treated in a tertiary-care hospital with those of patients
referred from secondary community hospitals for the same
suspected or confirmed diagnosis; and (ii) to determine
the accuracy of the diagnosis and adequacy of treatment in




A prospective, observational, cohort study was carried out
at Hospital Universitari Vall d’Hebron, a 1000-bed teaching
hospital in Barcelona (Spain) that has all the major medical
and surgical departments and is a referral centre for cardiac
surgery. All consecutive adult patients (‡18 years old) with a
diagnosis of definite or possible LSIE [14] treated in our cen-
tre between January 2000 and September 2009 were
enrolled in the study. Patients were identified from the infec-
tious diseases, cardiology and cardiac surgery departments,
the microbiology department blood culture registry, and the
echocardiography laboratory. Patients sent for surgery from
another centre at completion of antimicrobial treatment
were excluded. All interventions were carried out by the
same medical staff team over the entire study period, includ-
ing infectious disease specialists, microbiologists, cardiolo-
gists, and cardiac surgeons.
Data collection
Demographic, clinical, diagnostic, treatment and follow-up
data were obtained by detailed chart abstraction with the
use of standardized reporting forms, and entered into a data-
base created specifically for the purpose of this study (Micro-
soft Access 2000 (9.0.3821SR-1)).
Definitions
IE was defined as definite or probable according to the mod-
ified Duke criteria [14]. Patients were defined as transferred
if the diagnosis of IE was established or suspected in another
hospital. Healthcare-associated IE has been defined else-
where [10]. Patients receiving an antimicrobial regimen
included in the current American, European or Spanish
guidelines for this disease were classified as correctly trea-
ted. We also considered the use of daptomycin (at least
6 mg/kg daily) as being correct for the treatment of IE
caused by methicillin-resistant Staphylococcus aureus [15].
The Charlson index at admission, corrected by age [16],
was used to stratify overall comorbidity. The EuroSCORE
[17] was calculated for all patients with an indication for
surgery. Cardiac surgery was indicated according to the
American Heart Association [6] and European guidelines [7].
Only cardiac surgery performed during the same hospital
admission was included in the analysis.
IE complications were defined as the development of any
of the following conditions: (i) congestive heart failure (CHF)
(new condition or worsening of a known condition); (ii)
paravalvular complication (diagnosed by echocardiography or
during surgery); (iii) new conduction abnormality; (iv) stroke;
(v) systemic embolism other than stroke; and (vi) acute renal
failure, defined as a 50% increase in the baseline creatinine
concentration. In-hospital mortality was defined as death
from any cause during hospitalization.
Statistical analysis
Quantitative variables are reported as the mean (standard
deviation (SD)), or median and interquartile range (IQR).
The chi-square test (or Fisher’s exact test when appropriate)
was used to compare the distribution of categorical variables,
and Student’s t-test was used for continuous variables. For
variables with a non-normal distribution, we used the Mann–
Whitney test. Differences were considered to be significant
at a p-value of <0.05. In order to assess the influence of
inadequate antimicrobial treatment on in-hospital mortality,
this variable was adjusted by CHF and staphylococcal infec-
tion (two well-known risk factors) in a multivariate logistic
regression. Statistical analyses were performed with Micro-
soft SPSS-PC+, version 15.0 (SPSS, Chicago, IL, USA).
Results
During the period of the study, 337 consecutive episodes of
LSIE in 334 adult patients were treated in our centre. One
hundred and fourteen (33.8%) episodes occurred in patients
who had been transferred from 35 different community hospi-
tals: 100 were referred with an established diagnosis, and 14
to confirm the suspected diagnosis. In 14 of the remaining 223
episodes, patients were transferred with symptoms and signs
of endocarditis, but this condition was not suspected at the
original institution. The reasons for transfer are summarized
in Table 1. A comparison between episodes in those trans-
ferred and those not transferred is given in Tables 2 and 3.
Diagnostic accuracy in transferred patients
One hundred and five of 114 transferred patients (92.1%)
underwent transthoracic echocardiography (TTE) or transo-
esophageal echocardiography (TEE) at the original institution.
TTE alone was performed in 46 cases (43.8%) and TEE was
additionally performed in the remaining 59. In 42 of these
105 patients (40%), TTE or TEE performed in our hospital
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demonstrated a complication that had not been diagnosed at
the original institution (17 paravalvular abscesses, 16 severe
valve regurgitations, and nine valve perforations). Changes
were more likely in patients tested only with TTE at the ori-
ginal institution than in those additionally tested with TEE
(52.2% vs. 30.5%, p 0.025). The time between echocardiogra-
phy studies at the original institution and at our hospital did
not influence the rate of changes: the median interval
between studies was 7 days (IQR 4–15) in patients with
changes and 6 days (IQR 3–12) in patients without changes
(p not significant). Moreover, eight of 25 patients not initially
considered to have an indication for surgery were finally
operated on because of an initial mistake in the risk stratifi-
cation, in four cases because of a septic paravalvular compli-
cation not diagnosed at the original institution.
Management adequacy in transferred patients
Only 52 of the 114 (45.6%) transferred patients received
adequate antimicrobial treatment at the original institution.
Eleven patients did not receive any antimicrobial treatment,
and 51 received inadequate treatment. The median time for
which inappropriate treatment was given was 5 days (IQR 3–
10 days). The reasons for administration of inadequate treat-
ment or no treatment are shown in Table 4. In five episodes
of relatively penicillin-resistant viridans group streptococcal
LSIE, gentamicin was switched to teicoplanin, tobramycin or
streptomycin because of misjudgement (antibiogram showing
low resistance to gentamicin). Furthermore, two viridans
group streptococci episodes were treated as methicillin-
susceptible Staphylococcus aureus, one Corynebacterium jeikeium
TABLE 1. Reasons for transferring patients
Reasons n (%)
Patients diagnosed with or suspected of having infective endocarditis at the origi-
nal institution (n = 114)
Indication for surgery in patients with CHF 56 (49.1)
Other indications for surgery (myocardial abscess, large
vegetations plus systemic embolism)
33 (28.9)
Confirmed diagnosis of infective endocarditis 14 (12.3)
Received treatment in tertiary-care hospital 4 (3.5)
Haemorrhagic stroke 2 (1.8)
Other 5 (4.4)
Patients without suspected disease at the original institution (n = 14)
Fever of unknown origin 3 (21.4)
CHF 3 (21.4)
Acute ischaemia of inferior limbs 2 (14.3)
Obnubilation 2 (14.3)
Ischaemic cardiopathy 1 (7.1)
Blood culture persistently positive for Candida 1 (7.1)
Stroke 1 (7.1)
Mediastinitis after cardiothoracic surgery 1 (7.1)
CHF, congestive heart failure.
TABLE 2. Comparison between transferred cases and patients diagnosed and treated for left-sided infective endocarditis in
our hospital—demographics and predisposing factors
Transferred IE (n = 144) Non-transferred IE (n = 223) OR (95% CI) p
Duke IE criteria, n (%)
Definite endocarditis 103 (90.4) 188 (84.3) 1.74 (0.85–3.58) 0.130
Demographic variables
Female sex, n (%) 33 (28.9) 79 (35.4) 0.74 (0.46–1.21) 0.233
Mean age (years) (SD) 59.7 (15.3) 63.3 (16.6) 0.99 (0.97–1.00) 0.059
Duration of symptoms (days)
Median time to admission (IQR) 31.0 (7.0–71.0) 8.0 (3.0–31.5) <0.001
Median time to treatment (IQR), overall 32.5 (10.8–80.5) 9.0 (4.8–33.0) <0.001
Viridans group streptococci 48.5 (17.5–96.8) 18.0 (6.0–47.0) 0.017
Staphylococcus aureus 6.5 (3.8–21.3) 5.0 (2.8–8.0) 0.152
Enterococcus spp. 51.0 (32.0–104.5) 13 (6.0–42.0) 0.005
Coagulase-negative staphylococci 16.0 (9.0–61.3) 13.5 (5.3–27.0) 0.412
Comorbidities
Charlson index, median (IQR) 3.0 (1.0–4.0) 4.0 (2.0–6.0) <0.001
Diabetes mellitus, n (%) 24 (21.1) 47 (21.1) 1.00 (0.57–1.74) 0.999
Haemodialysis, n (%) 2 (1.8) 14 (6.3) 0.27 (0.06–1.19) 0.084
Neoplasm, n (%) 13 (11.4) 33 (14.8) 0.74 (0.37–1.47) 0.392
HIV infection, n (%) 1 (0.9) 11 (4.9) 0.17 (0.02–1.34) 0.092
Immunosuppressive therapy, n (%) 4 (3.5) 17 (7.6) 0.44 (0.15–1.34) 0.149
Source of infection, n (%)
HAIE 19 (16.7) 85 (38.1) 0.33 (0.19–0.57) <0.001
Community-acquired 95 (83.3) 138 (61.9)
Type of valve affected, n (%)
Prosthetic valve 18 (15.8) 52 (23.3) 0.62 (0.34–1.11) 0.109
Native valve 96 (84.2) 171 (73.7)
Affected valve, n (%)
Mitral alone 33 (28.9) 83 (37.2) 0.69 (0.42–1.12) 0.130
Aortic alone 60 (52.6) 93 (41.7) 1.55 (0.99–2.45) 0.057
Predisposing factor, n (%)
Congenital heart disease 14 (12.3) 13 (5.8) 2.26 (1.03–4.99) 0.043
Bicuspid aortic valve 11/14 (78.6) 8/13 (61.5)
Native valve predisposition 27 (23.7) 40 (17.9) 1.42 (0.82–2.46) 0.212
Previous IE episode 1 (0.9) 16 (7.2) 0.11 (0.02–0.88) 0.037
HAIE, healthcare-associated infective endocarditis; HIV, human immunodeficiency virus; IE, infective endocarditis; IQR, interquartile range; SD, standard deviation.
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case was treated as viridans group Streptococcus, and one viri-
dans group Streptococcus LSIE was treated as coagulase-nega-
tive Staphylococcus. In contrast, all non-transferred patients
received appropriate antimicrobial treatment once the diag-
nostic of IE was established. This was possible because of
daily communication between departments (cardiology, infec-
tious diseases, microbiology, and cardiac surgery).
Fifty-six patients (49.1%) were transferred because of an
indication for surgery for CHF. The median time between
heart failure onset and referral was 6 days (IQR 1–24.5 days),
and the median length of stay in the first hospital was 9 days
(IQR 5–13.8 days). Fifteen of these patients (26.8%) died after
referral. A higher percentage of non-survivors than survivors
had staphylococcal infections (12.2% vs. 66.7%, p <0.001) and
they were transferred earlier (mean days from heart failure
onset 9.0 (SD 12.9) vs. 19.7 (SD 26.1), p 0.047).
Comparison between transferred patients with adequate
treatment and those with inadequate or no treatment
The two subgroups (patients receiving inadequate or no anti-
microbial treatment (n = 62) and patients receiving adequate
treatment (n = 52)) did not differ in age, sex, baseline
comorbid status, rate of prosthetic infections, severity of
valve regurgitation, operations performed, or presence of
any complication. However, patients receiving inadequate or
no treatment had more healthcare-associated episodes
(24.2% vs. 7.7%, p 0.025), more infections caused by entero-
cocci (19.4% vs. 1.9%, p 0.018) and coagulase-negative staph-
ylococci (11.3% vs. 1.9%, p 0.085), fewer infections caused
by Streptococcus bovis (3.2% vs. 21.2%, p 0.009), a higher Eu-
TABLE 3. Comparison between transferred cases and patients diagnosed and treated for left-sided infective endocarditis in
our hospital—clinical characteristics and prognosis
Transferred
IE (n = 144)
Non-transferred
IE (n = 223) OR (95% CI) p
Aetiology, n (%)
Viridans group streptococci 38 (33.3) 52 (23.3) 1.64 (1.00–2.71) 0.050
Staphylococcus aureus 22 (19.3) 52 (23.3) 0.79 (0.45–1.38) 0.400
MRSA 4 (3.5) 12 (5.4) 0.64 (0.20–2.03) 0.448
Enterococcus spp. 13 (11.4) 31 (13.9) 0.80 (0.40–1.59) 0.520
Coagulase-negative staphylococci 8 (7.0) 24 (10.8) 0.63 (0.27–1.44) 0.271
Streptococcus bovis 13 (11.4) 13 (5.8) 2.08 (0.93–4.65) 0.075
No aetiology established 6 (5.3) 8 (3.6) 1.49 (0.51–4.41) 0.466
Streptococcus agalactiae 4 (3.5) 9 (4.0) 0.87 (0.26–2.87) 0.812
HACEK group 1 (0.9) 5 (2.2) 0.39 (0.05–3.34) 0.668
Other 9 (7.9) 29 (13.0) 0.57 (0.26–1.26) 0.161
Echocardiographic findings
Mean end-diastolic diameter (mm) (SD) 55.6 (7.2) 52.7 (8.0) 1.05 (1.02–1.09) 0.004
Mean left ventricular ejection rate (%) (SD) 59.4 (11.6) 58.7 (11.5) (0.98–1.03) 0.611
Mean PA systolic blood pressure (mmHg) (SD) 48.4 (14.0) 45.7 (16.6) (0.99–1.03) 0.221
Mean vegetation number (SD) 1.8 (1.2) 1.5 (1.1) 1.24 (1.01–1.51) 0.040
Largest vegetation mean diameter (mm) (SD) 16.0 (7.1) 12.3 (6.7) 1.08 (1.04–1.12) <0.001
Moderate/severe aortic regurgitation, n (%) 75 (65.8) 87 (39.0) 3.01 (1.88–4.82) <0.001
Moderate/severe mitral regurgitation, n (%) 64 (56.1) 98 (43.9) 1.63 (1.04–2.57) 0.035
Complications, n (%)
Any complication 108 (94.7) 176 (78.9) 4.81 (1.99–11.62) <0.001
CHF 78 (68.4) 87 (39.0) 3.39 (2.10–5.46) <0.001
Septic paravalvular complication 44 (38.6) 42 (18.8) 2.71 (1.64–4.49) <0.001
New conduction abnormality 24 (21.1) 32 (14.3) 1.59 (0.89–2.86) 0.120
Stroke 28 (24.6) 37 (16.6) 1.64 (0.94–2.85) 0.081
Systemic embolism other than stroke 32 (28.1) 75 (33.6) 0.77 (0.47–1.26) 0.300
Acute renal failure 49 (43.0) 61 (27.4) 2.00 (1.25–3.21) 0.004
Surgery
Surgery performed, n (%) 79 (69.3) 49 (22.1) 7.97 (4.79–13.26) <0.001
Surgery indicated, not performeda, n (%) 21 (18.4) 56 (25.1) 0.23 (0.13–0.43) <0.001
EuroSCORE, mean (SD) 8.9 (3.3) 10.6 (3.7) 0.87 (0.80–0.94) 0.001
Median intensive-care unit stay (days) (IQR) 3.0 (2.0–8.0) 0 (0–4.0) <0.001
Median length of stay (survivors) (days) (IQR) 42.0 (31.0–53.8) 37.0 (27.5–53.5) 0.218
In-hospital mortality, n (%) 26 (22.8) 70 (31.4) 0.65 (0.38–1.09) 0.100
CHF, congestive heart failure; HACEK, group including Haemophilus species, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens and Kingella kingae;
IE, infective endocarditis; IQR, interquartile range; MRSA, methicillin-resistant Staphylococcus aureus; PA, pulmonary artery; SD, standard deviation.
aSurgery not performed because of unacceptable surgical risk.
TABLE 4. Description of inadequate treatment or no
treatment
Reasons for no/inadequate treatment (n = 62) n (%)
Treatment not established in guidelines or consensus forums 17 (27.4)
Gentamicin (more days, higher dose, or full dosage in renal
failure)
12 (19.4)
Low b-lactam dose 8 (12.9)
No treatment despite established diagnosis and positive blood
cultures
6 (9.7)
Inadequate interpretation of antibiogram 5 (8.1)
Treatment for microorganism other than that isolated 4 (6.5)
Native valve infective endocarditis treated as prosthetic valve
endocarditis
4 (6.5)
No treatment despite established diagnosis because of
negative blood cultures
3 (4.8)
No treatment because blood cultures were not performed 2 (3.2)
b-Llactam administered orally 1 (1.6)
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roSCORE when surgery was indicated (9.4 vs. 8.2, p 0.065),
more positive valve cultures when operated on (27.3% vs.
11.4%, p 0.121), acute renal failure more often (51.6% vs.
32.7%, p 0.044), a longer median length of stay (43.5 days
(IQR 34.8–60.0) vs. 38.0 (IQR 26.8–48.5), p 0.047), and
greater in-hospital mortality (32.2% vs. 11.5%, p 0.011).
Predictors of outcome in transferred patients
The factors associated with in-hospital death by univariate
analysis are shown in Table 5. When adjusted by CHF and
staphylococcal infection in the multivariate logistic regres-
sion, inadequate or no antimicrobial treatment at origin was
a risk factor for in-hospital mortality (OR 3.3, 95% CI 1.1–
10.0, p 0.030).
Discussion
This article describes a contemporary series of patients with
LSIE treated in a tertiary-care hospital. To our knowledge,
this is the first study designed to evaluate the influence on
outcome of the accuracy of diagnosis and initial treatment of
IE. Because that our hospital is a reference centre for cardiac
surgery, approximately one-third of cases were transferred
from second-level community hospitals. Overall, transferred
patients were in better health, presented with CHF more
often, and underwent more operations with a lower risk;
nonetheless, mortality in this group was similar to that in the
higher-risk patients diagnosed and treated in our hospital, in
keeping with a previous epidemiological study [10]. Most
importantly, this is the first published study evaluating the
influence of inadequate antimicrobial therapy at the original
institution on outcome, and shows that it is an independent
risk factor for in-hospital mortality.
Patients were mainly referred for surgery because of the
presence of known complications of IE. Referral bias is a
common problem in studies on IE, as was established by
Steckelberg et al. [12] and confirmed recently by investiga-
tors from the International Collaboration on Endocarditis
[5]. Only a few studies, such as that by the Andalusian
TABLE 5. Association between characteristics of transferred patients and in-hospital death
Variable Non-survivors (n = 26) Survivors (n = 88)
Univariate analysis
OR (95% CI) p
Demographic variables
Female sex, n (%) 11 (42.3) 22 (25.0) 2.20 (0.88–5.50) 0.091
Mean age (years) (SD) 66.2 (12.2) 57.8 (15.6) 1.04 (1.01–1.08) 0.016
Source of infection, n (%)
HAIE 8 (30.8) 11 (12.5) 3.11 (1.09–8.85) 0.033
Community-acquired 16 (69.2) 77 (87.5)
Comorbidities
Charlson index, median (IQR) 4.0 (3.0–5.3) 2.0 (1.0–4.0) <0.001
Diabetes mellitus, n (%) 9 (34.6) 15 (17.0) 2.58 (0.97–6.87) 0.059
Type of valve affected, n (%)
Prosthetic valve 7 (26.9) 11 (12.5) 2.58 (0.88–7.54) 0.083
Native valve 19 (73.1) 11 (87.5)
Affected valve, n (%)
Mitral alone 11 (42.3) 22 (25.0) 2.20 (0.88–5.50) 0.091
Aetiology, n (%)
Viridans group streptococci 3 (11.5) 35 (39.8) 0.20 (0.06–0.71) 0.013
Staphylococcal infection 13 (50.0) 17 (19.3) 4.18 (1.64–10.62) 0.003
Echocardiographic findings
Mean end-diastolic diameter (mm) (SD) 51.8 (7.3) 56.6 (6.9) 0.90 (0.83–0.97) 0.007
Mean PA systolic blood pressure (mmHg) (SD) 55.0 (14.3) 46.4 (13.4) 1.05 (1.01–1.09) 0.024
Largest vegetation mean diameter (mm) (SD) 19.4 (7.2) 15.2 (6.8) 1.08 (1.01–1.17) 0.034
Moderate/severe aortic regurgitation, n (%) 13 (50.0) 62 (70.5) 0.42 (0.17–1.03) 0.057
Median days to treatment (IQR) 19.5 (5.8–63.0) 35.5 (11.5–91.8) 0.089
Inadequate or no antimicrobial treatment, n (%) 20 (76.9) 42 (47.7) 3.65 (1.34–9.96) 0.011
Complications, n (%)
Any complication 26 (100) 82 (93.2) NA 0.999
CHF 25 (96.2) 53 (60.2) 16.51 (2.14–27.46) 0.007
Septic paravalvular complication 14 (53.8) 30 (34.1) 2.26 (0.93–5.48) 0.073
New conduction abnormality 8 (30.8) 16 (18.2) 2.00 (0.74–5.40) 0.171
Stroke 8 (30.8) 20 (22.7) 1.51 (0.57–3.99) 0.404
Systemic embolism other than stroke 8 (30.8) 24 (27.3) 1.19 (0.46–3.08) 0.728
Acute renal failure 20 (76.9) 29 (33.0) 6.78 (2.46–18.71) <0.001
At origin 17 (65.4) 21 (23.9) 6.03 (2.34–15.51) <0.001
At origin because of gentamicin 6 (23.1) 9 (10.2) 2.63 (0.84–8.26) 0.097
Surgery
Surgery performed, n (%) 17 (65.4) 62 (70.5) 0.79 (0.31–2.01) 0.623
Surgery indicated but not performeda, n (%) 9 (34.6) 12 (16.2) 2.74 (0.99–7.57) 0.053
EuroSCORE, mean (SD) 12.3 (3.0) 7.6 (2.4) 1.74 (1.40–2.17) <0.001
Length of intensive-care unit stay, median (IQR) 7.0 (2.0–27.8) 3.0 (0.5–6.8) 0.041
CHF, congestive heart failure; HAIE, healthcare-associated infective endocarditis; IQR, interquartile range; NA, not applicable; PA, pulmonary artery; SD, standard deviation.
aSurgery not performed because of unacceptable surgical risk.
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Group for the Study of Cardiovascular Infections [18], have
investigated the problem in more detail, including all consec-
utive cases of IE diagnosed in community hospitals as well as
those diagnosed and treated in referral centres for cardiac
surgery.
In the multicentre study of Delahaye et al. [13], designed
with a slightly different objective, inappropriate antimicrobial
treatment in this population was reported to be 19.8% (in
the present study, 54.4% had inappropriate or no treatment),
and blood cultures were not performed before initiating
treatment in 27.6% of cases (in our series, 3.2% of the group
with inappropriate or no treatment). In addition, surgery was
delayed in five of 19 patients with severe heart failure or
fever persisting for more than 2 weeks despite antibiotic
therapy surgery. In our study, half of the patients referred
for CHF as an indication for surgery were transferred more
than 6 days after symptom onset. Thus, the difficulty in the
management of IE that we observed may well be occurring
in other second-level hospitals.
Echocardiography is one of the cornerstones of the diag-
nosis and management of IE. It is vital to establish one of
the two major diagnostic criteria [14], and some indications
for surgery are based on the findings of this test [6,7]. Com-
plications undiagnosed at the original institution were mainly
identified in patients in whom only TTE had been carried
out there, but additional complications were also detected
in 30% of those who had undergone TEE. Echocardiography
is an operator-dependent technique; thus, the divergences
may be explained by the more extensive experience in our
centre, and that fact that a standardized technique is used.
In addition, special attention should be given to prosthetic
valve endocarditis, in which the most feared echocardio-
graphic complications are paravalvular abscess and dehis-
cence, and for which delayed diagnosis can result in a
poorer prognosis.
In contrast, initiation of appropriate antimicrobial treat-
ment is a simple task once the causative microorganism has
been identified. Antimicrobial treatments for the most com-
mon causes of IE are well described in guidelines. Thus, it is
surprising that appropriate treatment was lacking in more
than half of the transferred patients. This rate is far from the
19.8% reported in the Delahaye study [13], but the reasons
(underdosage of b-lactam agents; antibiotics poorly adapted
to the microorganism or the antibiogram) are similar. The
importance of this shortcoming resides in the fact that an
error in prescribing the initial treatment was found to be an
independent risk factor for in-hospital mortality in these
patients (OR 3.3). Moreover, there were at least two addi-
tional consequences of erroneous initial treatment. First, the
median length of stay in surviving patients with inadequate or
no treatment was longer than in adequately treated patients.
Second, gentamicin misuse was linked to a higher rate of
acute renal failure, which is a risk factor for in-hospital mor-
tality in the univariate analysis. For this reason, and because
one of the most inadequately treated aetiologies in our
study, enterococcal infection, often occurs in elderly patients
with impaired renal function, we advocate the use of alterna-
tive antimicrobial therapy with proven effectiveness, such as
the combination of ampicillin and ceftriaxone to treat Entero-
coccus faecalis IE [6,19].
In light of the high incidence of erroneous antimicrobial
prescriptions found in this study, it is reasonable to assume
that other complex decisions might not have been properly
taken. IE is an uncommon disease, and despite the continu-
ously updated guidelines, treatment in many patients diverges
from the recommendations. Several instances of the creation
of multidisciplinary teams for the management of IE have
been described. Botelho-Nevers et al. [20] recently reported
a considerable decrease in mortality when a specific pro-
gramme was implemented. Despite the limitation of selection
bias pointed out by Tattevin et al. [21], the benefits of a
comprehensive approach to this difficult disease are worthy
of note. Similarly, one study conducted at a teaching hospital
without a cardiac surgery department showed that the intro-
duction of a multidisciplinary IE team, which included a con-
sultant cardiac surgeon, was associated with a significant
increase in referrals for surgery (from 14.5% to 34.5%) and a
decrease in in-hospital mortality (20.9–13.8%, p not signifi-
cant) [2].
The present study has some limitations. First, it was con-
ducted in a single reference centre, and the results may be
not applicable to other populations. Second, it is probable
that very low-risk patients without an indication for surgery
and a favourable outcome, as well as elderly patients and
those with severe comorbidities in which surgery entailed an
unacceptable risk of death, were not transferred. It is also
possible that some patients were not diagnosed at the origi-
nal institution. In consequence, the accuracy of the diagnosis
and management could not be evaluated in those cases.
Moreover, the use of different recommendations for the
treatment of our patients [6–8] could be a limitation that
influences prognosis. More studies (ideally multicentre stud-
ies) are needed to generalize these findings.
In conclusion, IE is a rare and severe condition that con-
tinues to be associated with high morbidity and mortality, as
a consequence of changes in its epidemiology. In this
context, attention should be paid to control of the modifi-
able risk factors for mortality. Early evaluation of each case
of IE by a multidisciplinary team experienced in this field will
improve the outcome of these patients. Thus, all cases of IE
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that are suspected or diagnosed at a second-level hospital
should lead to prompt contact with a referral centre.
Acknowledgements
We thank C. Cavallo for language support. N. Ferna´ndez-
Hidalgo, B. Almirante, M. N. Larrosa and A. Pahissa belong
to the Spanish Network for Research in Infectious Diseases
(REIPI RD06/0008). P. Tornos, M. T. Gonza´lez-Alujas and
A. Sambola belong to the Cooperative Network for
Cardiovascular Research (Red Cooperativa de Enfermedades
Cardiovasculares, RECAVA) of the Spanish National Institute
of Health (NCT 00624091).
Transparency Declaration
All authors declare that they have no conflicts of interest.
References
1. Tleyjeh IM, Abdel-Latif A, Rahbi H et al. A systematic review of popu-
lation-based studies of infective endocarditis. Chest 2007; 132: 1025–
1035.
2. Lo´pez-Dupla M, Herna´ndez S, Olona M et al. Clinical characteristics
and outcome of infective endocarditis in individuals of the general
population managed at a teaching hospital without cardiac surgery
facilities: study of 120 cases. Rev Esp Cardiol 2006; 59: 1131–1139.
3. Wang A, Athan E, Pappas PA et al. Contemporary clinical profile and
outcome of prosthetic valve endocarditis. JAMA 2007; 297: 1354–
1361.
4. Thuny F, Avierinos JF, Tribouilloy C et al. Impact of cerebrovascular
complications on mortality and neurologic outcome during infective
endocarditis: a prospective multicentre study. Eur Heart J 2007; 28:
1155–1161.
5. Murdoch DR, Corey GR, Hoen B et al. Clinical presentation, etiology,
and outcome of infective endocarditis in the 21st century. The Inter-
national Collaboration on Endocarditis-Prospective Cohort Study.
Arch Intern Med 2009; 169: 463–473.
6. Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis: diag-
nosis, antimicrobial therapy, and management of complications: a
statement for healthcare professionals from the Committee on Rheu-
matic Fever, Endocarditis, and Kawasaki Disease, Council on Cardio-
vascular Disease in the Young, and the Councils on Clinical
Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia,
American Heart Association: endorsed by the Infectious Disease
Society of America. Circulation 2005; 111: 394–434.
7. Habib G, Hoen B, Tornos P et al. Guidelines on prevention, diagnosis
and treatment of infective endocarditis (new version 2009). The task
force on the prevention, diagnosis, and treatment of infective endo-
carditis of the European Society of Cardiology. Eur Heart J 2009; 30:
2369–2413.
8. Valle´s F, Anguita M, Escribano MP et al. Practice guidelines of the
Spanish society of cardiology on endocarditis. Rev Esp Cardiol 2000;
53: 1384–1396.
9. Prendergast BD. The changing face of infective endocarditis. Heart
2006; 92: 879–885.
10. Ferna´ndez-Hidalgo N, Almirante B, Tornos P et al. Contemporary
epidemiology and prognosis of health care-associated infective endo-
carditis. Clin Infect Dis 2008; 47: 1287–1297.
11. Benito N, Miro´ JM, de Lazzari E et al. Health care-associated native
valve endocarditis: importante of non-nosocomial acquisition. Ann
Intern Med 2009; 150: 586–594.
12. Steckelberg JM, Melton LJ 3rd, Ilstrup DM, Rouse MS, Wilson WR.
Influence of referral bias on the apparent clinical spectrum of infec-
tive endocarditis. Am J Med 1990; 88: 582–588.
13. Delahaye F, Rial MO, de Gevigney G, Ecochard R, Delaye J. A critical
appraisal of the quality of the management of infective endocarditis.
J Am Coll Cardiol 1999; 33: 788–793.
14. Li JS, Sexton DJ, Mick N et al. Proposed modifications to the Duke
criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2002;
30: 633–638.
15. Kanafani Z, Boucher H, Fowler V et al. Daptomycin compared to
standard therapy for the treatment of native valve endocarditis.
Enferm Infecc Microbiol Clin 2010; doi:10.1016/j.eimc.2009.07.015.
16. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a
combined comorbidity index. J Clin Epidemiol 1994; 11: 1245–1251.
17. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon
R. European system for cardiac operative risk evaluation (Euro-
SCORE). Eur J Cardiothorac Surg 1999; 16: 9–13.
18. Ga´lvez-Acebal J, Rodrı´guez-Ban˜o J, Martı´nez-Marcos FJ et al. Prognos-
tic factors in left-sided endocarditis: results from the Andalusian
multicenter cohort. BMC Infect Dis 2010; 10: 17–24.
19. Gavalda` J, Len O, Miro´ JM et al. Brief communication: treatment of
Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann
Intern Med 2007; 146: 574–579.
20. Botelho-Nevers E, Thuny F, Casalta JP et al. Dramatic reduction in
infective endocarditis-related mortality with a management-based
approach. Arch Intern Med 2009; 169: 1290–1298.
21. Tattevin P, Donal E, Revest M. Can we really achieve a 1-year
mortality rate lower than 10% in patients with infective endocarditis?
Arch Intern Med 2010; 170: 211.
CMI Ferna´ndez-Hidalgo et al. Infective endocarditis and referral bias 775
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 769–775
